CLL

Clinical insights on shared decision-making practices and the importance of supportive care when treating patients with chronic lymphocytic leukemia.

A medical oncologist provides a comprehensive overview of treatment options for patients with relapsed/refractory chronic lymphocytic leukemia, including BTK inhibitors and CAR T-cell therapy.

An expert on chronic lymphocytic leukemia discusses adverse effects encountered by patients who are receiving BTK inhibitors or venetoclax-based regimens.

Josie Montegaard, MSN, AGPCNP-BC, provides clinical insights on her approach to counseling patients who are receiving treatment for chronic lymphocytic leukemia.

Dr Linhares discusses newer combination therapies for the treatment of patients with chronic lymphocytic leukemia, highlighting ibrutinib and venetoclax, which is being studied in the CAPTIVATE trial.

Turning the focus to ibrutinib-based therapy, Yuliya Linhares, MD, gives an overview of the RESONATE study.

Intimacy was always important in my relationship with my husband, and it continued to be even after my small lymphocytic lymphoma diagnosis.

Expert perspectives on the SEQUOIA study, which is investigating zanubrutinib in patients with chronic lymphocytic leukemia.

Yuliya Linhares, MD, discusses the CLL14 study, which is looking at venetoclax plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia.

Focusing on acalabrutinib-based treatment, Yuliya Linhares, MD, discusses results from the ELEVATE TN clinical trial.

A general overview of efficacy and safety data for current treatment options for patients with chronic lymphocytic leukemia.

Josie Montegaard, MSN, AGPCNP-BC, offers expert perspectives on treatment considerations in CLL, focusing on BTK inhibitors and venetoclax-based therapy.

Dr Linhares provides clinical insights on factors that guide treatment decisions for patients with chronic lymphocytic leukemia, such as comorbidities and disease biology.

Finding out that some family members have the BRCA gene makes me worried for them regarding the prospect of cancer.

After reading a book about how Imbruvica was revolutionized for SLL and CLL, I now have a greater appreciation for the drugs I receive.

Dr Linhares gives a comprehensive overview of tests a patient might expect to undergo at the time of diagnosis and why they are important.

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, introduce themselves and give an overview of chronic lymphocytic leukemia (CLL), highlighting symptoms and patient presentation.

When my doctor told me, "I want to talk to you about something," I suddenly felt worried — thankfully it was good news.

For 14 years, I've been dealing with small lymphocytic lymphoma, and want to maintain a healthier diet.

Breyanzi has been approved by the FDA for some previously treated patients with CLL or SLL — marking the first CAR-T cell therapy approved for this patient population.

My faith has helped guide me through chronic small lymphocytic lymphoma.

An oral suspension formula of Imbruvica received the green light from the Food and Drug Administration to be used in all approved indications.

I've been living with small lymphocytic lymphoma for 14 years now, but it has taught be some valuable lessons about life.

Certain antihypertensive medications may lower blood pressure in patients with blood cancer being treated with Imbruvica or other BTK inhibitors.

A CAR NK therapy made from cord blood showed promising responses in patients with relapsed or refractory B-cell malignancies.

BTK degrader NX-5948 has been granted Fast Track designation by the FDA to treat some adults with relapsed or refractory chronic lymphocytic leukemia or relapsed or refractory small lymphocytic lymphoma.

The top stories on chronic lymphocytic leukemia from 2023 included topics like BTK inhibitors, minimal residual disease status and approaches to care for various stages of the disease.

Managing a cancer support group isn't easy.

Where a patient lives may affect what kind of treatment they are offered for their CLL or SLL. However, second opinions and learning about one’s cancer diagnosis can help.

Brukinsa led to improved progression-free survival over Imbruvica in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, follow-up from the phase 3 ALPINE study showed.